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the original work isObjective: The objective of this study is to assess the risk of viral rebound in postpartum
women on suppressive combination antiretroviral therapy (cART).
Methods: Using data from the UK Collaborative HIV Cohort (UK CHIC) study and the
UK and Ireland National Study of HIV in Pregnancy and Childhood (NSHPC), women
with HIV-RNA 50 copies/ml or less at delivery in 2006–2011, who started life-long
cART during pregnancy (n¼321) or conceived on cART (n¼618), were matched by
age, duration on cART and time period, with at least one control (non-postpartum). The
cumulative probability of viral rebound (HIV-RNA >200 copies/ml) was assessed by
Kaplan–Meier analysis; adjusted hazard ratios (aHRs) for the 0–3 and 3–12 months
postdelivery (cases)/pseudo-delivery (controls) were calculated in Cox proportional
hazards models.
Results: In postpartum women who conceived on cART, 5.9% [95% confidence
interval (95% CI) 4.0–7.7] experienced viral rebound by 3 months, and 2.2%
(1.4–3.0%) of their controls. The risk of viral rebound was higher in postpartum women
than in controls during the first 3 months [aHR 2.63 (1.58–4.39)] but not during the
3–12 months postdelivery/pseudo-delivery. In postpartum women who started cART
during pregnancy, 27% (22–32%) experienced viral rebound by 3 months, and 3.0%
(1.6–4.4%) of their controls. The risk of viral rebound was higher in postpartum women
than in controls during both postdelivery/pseudo-delivery periods [<3 months: aHR
6.63 (3.58–12.29); 3–12 months: aHR 4.05 (2.03–8.09)].
Conclusion: In women on suppressive cART, the risk of viral rebound is increased
following delivery, especially in the first 3 months, which may be related to reduced
adherence, indicating the need for additional adherence support for postpartum
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Historically, women living with HIV not yet eligible for
life-long combination antiretroviral therapy (cART) used
short-course cART or zidovudine monotherapy in
pregnancy to prevent mother-to-child transmission,
before initiating life-long treatment when their CD4þ
cell count reached a specified level. However, with
expanding CD4þ criteria for treatment initiation, the
number of women already on life-long cART at
conception or who are eligible to start when diagnosed
during pregnancy has increased [1–3]. Since 2013, the
WHO has recommended that in low and middle-income
countries, all pregnant women not yet on treatment start
life-long cART [4]. However, in the UK, the use of
short-course cART in pregnancy remains an option for
women with a CD4þ cell count above 350 cells/ml.
Pregnant women with a CD4þ cell count of 350–
500 cells/ml have the option of continuing cART use
if there are no contraindications such as poor adherence,
as are women with a CD4þ cell count more than
500 cells/ml with a discordant partner [5]. Thus, an
increasing proportion of women now remain on cART
after pregnancy.
Viral rebound generally occurs rapidly following cessation
of short-course cART after delivery [6–9]. However,
viral rebound has also been observed in postpartum
women remaining on cART, even when viral suppression
was achieved in pregnancy [9–11]. Using pooled data
from two observational studies, we assess, among women
on suppressive cART, the risk of viral rebound in women
with a pregnancy in the previous year and in matched
controls who had not been pregnant, with the postpartum
group stratified by timing of cART initiation (before or
during pregnancy).Materials and methods
Data collection
The UK Collaborative HIV Cohort (UK CHIC) study is
an ongoing observational study of adults attending HIV
clinical care, which annually collates pseudonymised data
from (currently 19) UK-based HIV clinics. Data include
all viral load measurements, CD4þ cell counts, hepatitis B
virus (HBV)/hepatitis C virus (HCV) coinfection status,
ART drug regimen and demographic information. The
UK and Ireland’s National Study of HIV in Pregnancy
and Childhood (NSHPC) is a comprehensive, observa-
tional, active surveillance study of HIV-positive women
accessing antenatal care, with data reported by all
maternity units in the UK and Ireland [12], including
ethnicity, age and expected delivery date, details of ART
use, CD4þ cell counts and viral loads in pregnancy. Both
studies had ethics approval and informed consent was
not required.Record linkage between these two pseudonymised
datasets is based on an algorithm that utilizes basic
demographic and clinical data. Since 2010, linkage was
undertaken yearly using the most recent datasets [13].
A woman was categorized as having attended for clinical
care if any viral load or CD4þ cell count data were
reported to UK CHIC during the period of interest.
ARTuse at conception, delivery and within 6 months of
delivery was assessed using data from both studies.
Women with a pregnancy resulting in a live birth in
2006–2011, an HIV-RNA 50 copies/ml or less at latest
viral load 3 months or less before delivery and who
remained on cART (use of at least three ART drugs) for at
least 6 months after delivery and with at least one viral
load measurement in the year after delivery were included
in this analysis, including only a woman’s earliest
pregnancy meeting the criteria.
Two controls were sought from the UK CHIC dataset for
each postpartum woman. Controls were HIV-positive
women accessing HIV-related care who had not recently
been pregnant. For womenwho had conceived on cART,
controls were matched on age (by year), calendar year and
number of years since starting life-long ART. For women
who started life-long cART in pregnancy, controls were
matched on the basis of age (grouped as 16–19; 20–24;
25–29; 30–34; 35–39; 40–44; 45–49 years), calendar
year (grouped as 2006–2007; 2008–2009; 2010–2011),
months since starting treatment (grouped as 0 to <3; 3 to
<6; 6 to<9 months) and CD4þ cell count when starting
treatment (grouped as 200; 201–350; 351–500;
>500 cells/ml).
To select suitable controls, reference dates were created by
splitting the period 2006–2011 into equal-sized intervals
and establishing each woman’s clinical characteristics (of
interest) on each date. The period was split into 3-month
intervals, to find controls for women conceiving on
cART, and 1-month intervals, for women starting cART
in pregnancy. For controls, the reference date was used as
the pseudo-delivery date. Eligibility criteria for controls
were: not currently pregnant, not pregnant within the
previous year, latest viral load 50 copies/ml or less, at least
one viral load measurement in the following year and on
cART for at least the following 6 months. If multiple
potential controls were identified, two were selected at
random. For postpartum women conceiving on cART,
women could act as controls on multiple occasions for
non-overlapping time periods.
The primary outcome was viral rebound (defined as a
single measure of HIV-RNA >200 copies/ml) within
12 months of delivery (postpartum women) or pseudo-
delivery (controls). In sensitivity analysis, viral rebound
was defined as a single measure of HIV-RNA more than
1000 copies/ml.
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Characteristics of postpartum women and controls were
compared using the chi-square test for categorical
variables and Kruskal–Wallis test for continuous (non-
normally distributed) variables. Kaplan–Meier analysis
was used to assess the cumulative probability of viral
rebound and Cox proportional hazards models to
calculate crude and adjusted hazard ratios (aHRs). As
the Kaplan–Meier analyses suggested that hazards were
likely to diverge after 3 months, separate models are
presented for the periods less than 3 and 3–12 months
postdelivery/pseudo-delivery, with the latter model
including only women who had not experienced viral
rebound or censoring during the less than 3-month
period. In unadjusted analyses, the baseline characteristics
assessed were postpartum status (postpartum/control),
CD4þ cell count category, type and duration of
ART regimen, parity (the number of live births since
HIV diagnosis), HBV/HCV coinfection, ethnicity and
exposure group. Follow-up was censored at 12 months
postdelivery/pseudo-delivery, if a woman died, inter-
rupted ART or became pregnant again, whichever
occurred first. In sensitivity analysis, follow-up was
also censored if the ART regimen was altered in any
way.Results
Postpartum women conceiving on combination
antiretroviral therapy and controls
There were 623 postpartum women who conceived on
cART, with two controls identified for 607, only one for
11 and none for five women, giving a total of 1225
controls.
The postpartum women and controls were similar with
regard to age, year and duration on cART (the matching
characteristics) (Table 1). They were also similar with
regard to time since HIV-diagnosis (median 5.9 years),
type of regimen used [overall, 55% used a nonnucleoside
reverse transcriptase inhibitor (NNRTI)-based regimen],
the percentage with HBV/HCV coinfection (7% overall)
and ethnic group (73% black-African overall). The
two groups differed with regard to HIV exposure
category, parity, latest CD4þ cell count and use of
efavirenz (EFV).
In the month following delivery/pseudo-delivery, 10%
(64/618) of postpartum women had a viral load
measurement and 26% (320/1225) of controls
(P< 0.001). After 3 months, 70% (435/618) of post-
partum women and 70% (862/1225) of controls had had
at least one viral load measurement (P¼ 0.99). The
median number of viral load measurements overall was
3 [interquartile range (IQR) 2–4] for both groups
(P¼ 0.11).Viral rebound in postpartum women conceiving
on combination antiretroviral therapy and
controls
A larger percentage of postpartum than control women
experienced viral rebound [postpartum: 10.7% (66/618);
controls: 7.4% (91/1225)]. The cumulative probability of
viral rebound at 1, 3 and 6 months postdelivery/pseudo-
delivery was 1.1% [95% confidence interval (95% CI)
0.3–2.0], 5.9% (95% CI 4.0–7.7) and 8.6% (95% CI
6.3–10.8), respectively, in postpartum women, and 0.9
(95% CI 0.0–1.4), 2.2% (95% CI 1.4–3.0) and 4.5%
(95% CI 3.3–5.6) in controls (Fig. 1a).
In adjusted analysis, the risk of viral rebound in the
0–3 months postdelivery/pseudo-delivery was associated
with postpartum status, calendar year and CD4þ cell
count (Table 2). Postpartum women were more likely to
experience viral rebound than controls (aHR 2.63),
although the risk of viral rebound itself decreased in later
calendar years (aHR 0.81 per later year). A CD4þ cell
count of 200 cells/ml or less at delivery/pseudo-delivery
was also significantly associated with viral rebound (aHR
2.89).
The risk of viral rebound in the 3–12 months
postdelivery/pseudo-delivery was associated with years
since HIV diagnosis, type of drug regimen and number of
drugs. In this subgroup, who had maintained viral
suppression for at least 3 months, there was no statistically
significant association between viral rebound and post-
partum status. Women who were diagnosed with HIV
more than 10 years ago were more likely to experience
viral rebound than women diagnosed 2–10 years ago
(aHR 1.83). Women on a drug regimen containing at
least four drugs were more likely to experience viral
rebound than women on a triple regimen (aHR 2.41) as
were women on a protease inhibitor-based regimen
compared with women on a NNRTI-based regimen
(aHR 1.89). The use of EFV was not associated with viral
rebound and was not included in the model.
Postpartum women starting combination
antiretroviral therapy in pregnancy and controls
There were 363 postpartum women who started cART
during pregnancy, with two controls identified for 247,
one for 74 and none for 42 women, giving a total of
568 controls.
Postpartum women and controls were similar with regard
to age, year, duration on cART and CD4þ cell count
when starting cART (the matching characteristics)
(Table 1). They were also similar with regard to the
type of drug regimen used but differed with regard to
ethnicity, exposure category, parity, HBV/HCV coin-
fection, duration since HIV diagnosis and latest CD4þ
cell count. On average, postpartum women had been
diagnosed more recently, had a higher median CD4þ cell
count (391 vs. 350 cells/ml), were less likely to use EFV
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ig. 1. Kaplan–Meier plot showing cumulative probability of viral rebound among women on antiretroviral therapy: post-
artum women (black line) and controls (grey line).F
pTable 2. Adjusted hazard ratios for viral rebound in postpartum women conceiving on antiretroviral therapy and controls stratified by time since
delivery.
Baseline characteristic at delivery/pseudo-delivery
<3 months since
delivery/pseudo-delivery
3–12 months since
delivery/pseudo-delivery
aHR (95% CI) P aHR (95% CI) P
Group Control Reference <0.001 Reference 0.76
Postpartum 2.63 (1.58–4.39) 0.93 (0.59–1.47)
Calendar year (per additional year) 0.81 (0.70–0.95) 0.01 0.96 (0.84–1.09) 0.50
Age (per 10 additional years) 0.93 (0.55–1.55) 0.77 0.84 (0.55–1.28) 0.42
Ethnicity Black African Reference 0.41 Reference 0.59
White 1.79 (0.87–3.71) 0.75 (0.36–1.57)
Black Caribbean 1.52 (0.36–6.35) 0.45 (0.06–3.28)
Other/NK 1.34 (0.62–2.91) 0.69 (0.33–1.45)
Exposure category Heterosexual sex Reference 0.63 Reference 0.87
Injecting drug use 0.41 (0.05–3.72) 0.73 (0.14–3.84)
Other/NK 0.56 (0.08–4.17) 1.21 (0.45–3.25)
Previous live birth 1.31 (0.79–2.20) 0.10 1.37 (0.89–2.11) 0.16
HBV/HCV coinfected 1.43 (0.58–3.55) 0.44 1.25 (0.59–2.65) 0.57
Latest CD4þ cell count (cells/ml) 200 2.89 (1.14–7.31) 0.10 2.05 (0.96–4.34) 0.05
201–350 1.74 (0.88–3.46) 1.12 (0.65–1.95)
351–500 1.79 (0.96–3.36) 0.64 (0.36–1.13)
>500 Reference Reference
Duration of ART use 8–12 months 1.34 (0.56–3.25) 0.19 0.98 (0.41–2.34) 0.77
1–4 years Reference Reference
5 years 0.57 (0.29–1.13) 0.83 (0.50–1.37)
Time since HIV diagnosis 8–23 months 0.66 (0.25–1.74) 0.69 1.66 (0.82–3.37) 0.04
2–9 years Reference Reference
10 years 1.04 (0.49–2.21) 1.83 (1.08–3.09)
Type of ART regimen PI 1.13 (0.66–1.93) 0.96 1.89 (1.19–3.00) 0.06
NRTI – 0.92 (0.12–6.87)
NNRTI Reference Reference
Other 0.95 (0.38–2.34) 1.39 (0.66–2.95)
Number of drugs in the regimen 2 2.36 (0.51–11.0) 0.17 2.17 (0.73–6.50) 0.01
3 Reference Reference
4 1.86 (0.91–3.81) 2.41 (1.36–4.25)
Baseline refers to the delivery date (postpartum women) or pseudo-delivery date (controls). aHR, adjusted hazard ratio; ART, antiretroviral therapy;
CI, confidence interval; NK, not known; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase
inhibitor; PI, protease inhibitor.
2274 AIDS 2015, Vol 29 No 17and were less likely to have had a previous live birth (since
HIV diagnosis) (Table 1).
More than half [53% (171/321)] of postpartum women
were diagnosed with HIV during the recent pregnancy, of
whom 65% (111/171) had a CD4þ cell count less than
350 cells/ml when starting cART, with 47% (81/171)
having a CD4þ cell count less than 200 cells/ml. Inwomen
already diagnosed when they became pregnant, 59%
(89/150) had a CD4þ cell count less than 350 cells/ml
when starting cART, with 32% (48/150) having a CD4þ
cell count less than 200 cells/ml; of these, almost two-thirds
[65% (98/150)] attended care at aUKCHIC site in theyear
prior to the pregnancy, of whom 53% (52/98) started
cARTwith a CD4þ cell count less than 350 cells/ml.
In the month following delivery/pseudo-delivery, 14%
(44/321) of postpartum and 27% (152/568) of controls
(P< 0.001) had a viral load measurement. At 3 months
postdelivery/pseudo-delivery, 80% (256/321) of post-
partum women and 79% (450/568) of controls had had at
least one viral load measurement (P¼ 0.85). The median
number of viral load measurements in the year following
delivery/pseudo-delivery was 3 (IQR 2–4) for the
postpartum women and 3 (3–4) for the controls
(P< 0.001).
Viral rebound in postpartum women starting
combination antiretroviral therapy in pregnancy
and controls
A larger percentage of postpartum women experienced
viral rebound than controls [postpartum: 37.1% (119/
321); controls: 9.2% (52/568)]. The cumulative prob-
ability of viral rebound at 1, 3 and 6 months postdelivery/
pseudo-delivery was 1.9% (95% CI 0.4–3.5), 27% (95%
CI 22–32) and 35% (95% CI 30–41), respectively, in
postpartum women, and 1.1% (95% CI 0–1.9), 3.0%
(95% CI 1.6–4.4) and 4.8% (95% CI 3.0–6.6),
respectively, in controls (Fig. 1b).
In adjusted analysis, the risk of viral rebound in the first 3
months postdelivery/pseudo-delivery was associated with
postpartum status (aHR 6.63 for postpartumwomen) and
CD4þ cell count (aHR 0.18; CD4þ cell count <200 vs.
>500 cells/ml) (Table 3).
The risk of viral rebound in the 3–12 months
postdelivery/pseudo-delivery was associated with post-
partum status (aHR 4.05 for postpartum women),
calendar year (aHR 0.83 per later year), age (aHR
0.51 per 10 additional years) and ethnicity (aHR 2.94 for
women of black-Caribbean ethnicity) (Table 3).
The findings were not affected when, in sensitivity
analysis, follow-up was censored at any regimen change.
In sensitivity analysis, when viral rebound was defined
as HIV-RNA more than 1000 copies/ml, similarassociations were observed, although some lost statistical
significance. The association between age and viral
rebound became statistically significant for women who
had started cART in pregnancy and controls [0–3 months
postdelivery/pseudo-delivery: aHR 0.46 (0.24–0.88) per
10 additional years]. Postpartum status remained associated
with viral rebound when 143 women (46 postpartum
and 97 controls) with previous cART experience were
excluded.Discussion
We show that HIV-positive women on cARTwith a live-
born infant in the preceding year and an undetectable
viral load at delivery had a higher risk of viral rebound
than matched control women who had not recently been
pregnant. Among women already on cART at con-
ception, the risk of viral rebound was 2.6-fold higher in
the first 3 months after delivery than among matched
controls, but similar in the 3–12 months after delivery. In
contrast, among women who started cART during
pregnancy, viral rebound risk was 6.6-fold higher than
matched controls during the first 3 months and 4.1-fold
higher 3–12 months after delivery. A number of studies
have observed a high prevalence of viral rebound in
postpartum women remaining on cART [7,10,14], but
this study is the first to compare the risk of viral rebound
in postpartum women with rates seen in a demographi-
cally matched group of non-postpartum women.
Overall, 9% of women who conceived on cART
experienced viral rebound within 6 months of delivery,
less than in a Brazilian study in which 15% (nine out of
52) of postpartum women, who conceived on and
remained on cART after pregnancy, developed viral
rebound (0.5 log10 increase) at 6 months postpartum [14].
This difference may be because women in the Brazilian
study had more advanced disease and not all had achieved
viral suppression during pregnancy. Two further studies
[7,10] reported that 19 and 18% (respectively) of
postpartumwomen who remained on cARTexperienced
viral rebound (defined as 0.7 log10 increase at 24 weeks
postpartum and 0.5 log10 increase at 6–12 weeks
postpartum, respectively). However, neither of these
studies stratified by timing of cART initiation (before or
during the pregnancy), which limits comparison with
our study.
Physiological changes during pregnancy and at delivery
may result in a temporary viral load peak and may have
contributed to the increased incidence in the first
3 months after delivery. However, this temporary peak
is most likely to occur shortly after delivery [8], a time
during which few women in our study had a viral load
measurement. Also, this would not explain the ongoing
increased risk of viral rebound after 3 months among
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Table 3. Adjusted hazard ratios for viral rebound in postpartum women starting antiretroviral therapy during pregnancy and controls stratified
by time since delivery.
Baseline characteristic at delivery/pseudo-delivery
<3 months since
delivery/pseudo-delivery
3–12 months since
delivery/pseudo-delivery
aHR (95% CI) P aHR (95% CI) P
Group Control Reference <0.001 Reference <0.001
Postpartum 6.63 (3.58–12.3) 4.05 (2.03–8.09)
Calendar year (per additional year) 1.02 (0.90–1.16) 0.72 0.83 (0.69–0.99) 0.04
Age (per 10 additional years) 0.71 (0.48–1.05) 0.08 0.51 (0.29–0.90) 0.02
Ethnicity Black African Reference 0.81 Reference 0.19
White 0.68 (0.29–1.61) 1.29 (0.52–3.22)
Black Caribbean 1.16 (0.50–2.73) 2.94 (1.11–7.76)
Other/NK 0.97 (0.49–1.91) 1.19 (0.52–2.73)
Exposure category Heterosexual sex Reference 0.41 Reference 0.66
Injecting drug use 4.65 (0.49–44.1) 2.37 (0.25–22.6)
Other/NK 1.00 (0.35–2.87) 1.38 (0.47–4.10)
Previous live birth 1.44 (0.78–2.65) 0.24 1.78 (0.48–6.56) 0.39
HBV/HCV coinfected 0.71 (0.21–2.39) 0.58 1.05 (0.30–3.65) 0.94
Latest CD4þ cell count (cells/ml) 200 0.18 (0.07–0.48) <0.001 0.73 (0.32–1.66) 0.35
201–350 0.39 (0.22–0.70) 0.70 (0.33–1.47)
351–500 0.81 (0.49–1.32) 0.44 (0.18–1.08)
>500 Reference Reference
Duration of ART use 0–2 months 0.82 (0.49–1.38) 0.76 0.91 (0.44–1.87) 0.35
3–5 months Reference Reference
6–8 months – 0.74 (0.26–2.14)
Time since HIV diagnosis 8–23 months 0.83 (0.51–1.35) 0.73 1.11 (0.55–2.22) 0.62
2–9 years Reference Reference
10 years 1.08 (0.37–3.11) 0.41 (0.05–3.24)
Type of ART regimen PI 0.83 (0.51–1.36) 0.90 1.34 (0.69–2.60) 0.86
NRTI – –
NNRTI Reference Reference
Other 0.89 (0.32–2.52) –
Use of EFV-containing regimen 0.20 (0.07–0.60) 0.004 0.88 (0.38–2.06) 0.77
Number of drugs in the regimen 3 Reference 0.86 Reference 0.86
4 1.11 (0.34–3.65) 0.88 (0.20–3.84)
Baseline refers to the delivery date (postpartum women) or pseudo-delivery date (controls). aHR, adjusted hazard ratio; ART, antiretroviral therapy;
CI, confidence interval; EFV, efavirenz; HBV, hepatitis B virus; HCV, hepatitis C virus; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI,
nucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor.women who started cART in pregnancy or the much
higher incidence in women who started cART in
pregnancy than women conceiving on cART. The more
likely explanation for the increase in viral rebound
incidence following pregnancy is reduced adherence to
cART. Studies have observed a fall in adherence following
pregnancy [10,15,16], when the risk of vertical trans-
mission has passed (if breastfeeding is avoided) and the
demands of looking after the baby are high. Treatment
interruptions and changes to medication are also more
likely in this period [10]. When, in sensitivity analysis,
follow-up was censored if the regimen was changed, the
association between post-pregnancy status and viral
rebound remained.
Older age was associated with a decreased risk of viral
rebound in women who started ART in pregnancy and
their controls. This is likely to be a result of better drug
adherence in older women [17–19].
Engagement with HIV care may have also been reduced
following pregnancy; in our observational study, data
were collected as part of HIV clinical care. We used theaverage number of viral load measurements recorded as a
proxy for clinic attendance. For all groups, the median
number of viral loads was three in the postdelivery/
pseudo-delivery year. However, for women who recently
started cART, there was evidence that postpartum
women attended care less often than controls
(P< 0.001 for the distribution of viral load measure-
ments). Previous studies have noted low attendance rates
in clinical care in the 3 months following childbirth [20]
and delay in seeking HIV care [21] or inability to
complete postpartum follow-up [22] among women with
children in the household.
We cannot rule out resistance as the reason for viral
rebound; however, in sensitivity analysis excluding
women with known previous exposure to ART,
postpartum status remained significantly associated with
an increased risk of viral rebound.
In women who started cART in pregnancy and their
controls, the risk of viral rebound in the first 3 months
after delivery/pseudo-delivery was lower in women with
a low CD4þ cell count than in women with a high CD4þ
2276 AIDS 2015, Vol 29 No 17cell count. Despite only including women who,
according to the data, remained on cART for at least
6 months, some discontinuations may not have been
recorded in the clinical notes. A woman’s CD4þ cell
count at cART initiation could indirectly affect
adherence; for example, women with a high CD4þ cell
count may not perceive the need for perfect adherence as
much as women starting cART with a low CD4þ cell
count. In some settings wherein WHO Option Bþ has
been implemented, high rates of lost-to-follow-up have
been observed among pregnant women starting life-long
cARTwith a high CD4þ cell count [23,24]. We do not
know whether a similar incidence of postpartum viral
rebound would occur if all pregnant women not yet on
ART started long-term treatment in pregnancy, as is
increasingly the case in low and middle-income settings
[4]. Remaining on treatment after pregnancy may be
beneficial for the woman’s health and to minimize HIV
transmission risk in subsequent pregnancies [25,26]. The
PROMISE study is currently assessing the benefits, in a
resource-limited settings, of women with higher CD4þ
cell counts remaining on cART after delivery (Trial
reference: NCT01061151).
For women who started cART in pregnancy and their
controls, a quadruple regimen was associated with an
increased risk of viral rebound in the 3–12 months
postdelivery/pseudo-delivery. As the standard first-line
treatment in the UK during the study period was a triple
regimen (wherein ritonavir use as a pharmacological
booster is not counted as a component of the regimen)
[27], use of a quadruple regimen suggests that they were
on a subsequent regimen due to developing resistance or
problems with a previous regimen/s. Adherence could
be more of an issue for women on a quadruple regimen,
as adherence is negatively associated with pill burden
[28].
In both groups, fewer postpartum women were on an
EFV-containing regimen than the controls. Until
recently, EFV has been avoided in pregnancy and in
women planning a pregnancy due to the possible risk to
foetal development [29], although a recent meta-analysis
found no increase in birth defects with EFV use [30]. In
women who started ART in pregnancy and their
controls, use of EFV was associated with a lower risk
of viral rebound in the first 3 months postdelivery/
pseudo-delivery. No such association was found in
women who had conceived on ART.
Although several relevant variables were included in our
adjusted model, we may not have accounted for all
potential confounders. To avoid detecting viral blips, viral
rebound is often defined on the basis of two consecutive
HIV-RNA more than 200/400/1000 copies/ml; we
were unable to take this approach due to the limited
number of viral load measurements reported in this
group.Increased viral load following pregnancy could have a
detrimental impact on women’s health and future
treatment options and increases the risk of transmission
to an HIV-negative partner, or to the infant, if the mother
chooses to breastfeed. Therefore, our findings indicate a
need for additional support for ART adherence and to
remain engaged in regular HIV clinical care, which could
include support from clinicians, specialist nurses and peer
support (via charities) from women living with HIV who
have experience of taking ART after pregnancy. The
findings of this study suggest that adherence support is
particularly needed bywomen starting life-long treatment
during pregnancy, especially younger women. It is
encouraging that the risk of viral rebound was lower
in later years of the study, indicating that adherence may
have improved over time and that regimens have become
more forgiving to lapses in adherence. The UK CHIC
study does not collect data on pill burden or use of fixed-
dose regimens (FDRs), so these could not be assessed as
potential factors associated with viral rebound. However,
other studies have found that use of a single-pill regimen
can improve adherence [31]. For pregnant women
starting long-term cART, a once-a-day FDR may
promote good adherence. Regimens more forgiving to
poor adherence could also be considered as the initial
regimen. Further studies are required to identify the most
effective strategies for improving postpartum ART
adherence.
In conclusion, in women on suppressive cART, the risk of
viral rebound is higher in postpartum women than in
similar women who have not recently had a pregnancy.
This may be a result of reduced adherence to ART,
highlighting the need for additional adherence support
for pregnant and postpartum women remaining on
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